Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses ...Middle East

Medscape - News
The main composite renal endpoint from VERTIS CV didn't show significant benefit from ertugliflozin over placebo, but in additional analyses showed kidney benefits from this SGLT2 inhibitor. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Ertugliflozin: Renal Benefits in Additional VERTIS CV Analyses )

Apple Storegoogle play

Also on site :



Latest News